• (PLX AI) – Genmab's recent share slump is a buying opportunity, analysts at Nordea said, maintaining an unchanged price target of DKK 3,191.
  • • Investors should add to positions ahead of the J&J Pharma Business Review day on Nov. 18, Nordea said
  • • Genmab has historically performed well after such events: Nordea
  • • Price target implies 17% upside

Quelle: PLX AI